BUY Glenmark Pharmaceuticals — Prakash Gaba

Entry₹2,268Inferred
Target₹2,300
Total upside +1.41% (call closed)
Stop loss₹2,240-1.23% risk
Exit₹2,2408 Jul 2026, 2:00 pm
Stop-loss hit-1.23%

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 4:57 pm IST
4 supporting0 opposing
Supports the BUY call (4)

2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·7 Jul · today

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·7 Jul · yesterday

Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial.

NSE · Press Release·6 Jul · 2d ago

(opens in new tab)

Glenmark Pharmaceuticals Ltd is advancing its Multi-Country Phase 3 Clinical Trial of Trastuzmab rezetecan in Platinum-Resistant Ovarian Cancer.

BSE · Company Update·2 Jul · 6d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.